Edwards Lifesciences赞扬CMS NCD经导管主动脉瓣置换术

2026-09-11 06:33

Edwards Lifesciences (EW) said that an updated CMS national coverage determination will ease patient access to transcatheter aortic valve replacement.
The NCD states that CMS will now cover TAVR for symptomatic severe aortic valve stenosis (aortic stenosis) without the coverage with evidence development requirement. Also, it expands coverage of TAVR to asymptomatic severe aortic stenosis with coverage with evidence development.
In addition, coverage criteria dealing with pre-procedural patient assessment, intraoperative requirements, and operator and hospital procedural volume requirements have been revised.
"Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team," the company said in a news release.
"The modernized policy recognizes the importance of timely care by supporting a more streamlined patient care journey and giving Heart Teams greater flexibility to apply their expertise to both patient evaluation and treatment based on each patient’s clinical needs."
Edwards noted that it “has confidence” in its 2026 guidance, adding that 2027 guidance will come in December at its investor conference.

More on Edwards Lifesciences